First National Bank of Omaha Takes Position in Lantheus Holdings, Inc. $LNTH

First National Bank of Omaha bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 9,299 shares of the medical equipment provider’s stock, valued at approximately $477,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Elevation Point Wealth Partners LLC bought a new stake in Lantheus in the 2nd quarter valued at about $26,000. Osterweis Capital Management Inc. acquired a new stake in Lantheus in the 2nd quarter valued at approximately $36,000. Hantz Financial Services Inc. raised its stake in Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 396 shares in the last quarter. First Horizon Corp acquired a new position in shares of Lantheus during the third quarter valued at $26,000. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Lantheus by 190.2% during the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after purchasing an additional 698 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of LNTH opened at $73.18 on Friday. The company has a 50-day moving average of $67.10 and a two-hundred day moving average of $59.57. The stock has a market cap of $4.85 billion, a price-to-earnings ratio of 30.75 and a beta of -0.08. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $111.29.

More Lantheus News

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: TD Cowen reaffirmed coverage and updated its financial model around upcoming Q4 results; the firm cut its price target to $75 but keeps a Buy rating, providing analyst support for the stock. TD Cowen Updates Financial Model
• Positive Sentiment: Brokerage consensus remains favorable — Lantheus has a “Moderate Buy” consensus from analysts, which can underpin demand into earnings. Consensus Rating: Moderate Buy
• Positive Sentiment: Technical/relative-strength screens show improving momentum for LNTH, which can attract momentum and quant flows. Stocks with Rising Relative Strength
• Neutral Sentiment: Lantheus is set to report quarterly results this week; earnings and guidance will likely be the primary near-term catalyst and could drive volatility. Earnings Release Notice
• Neutral Sentiment: Analyst modeling updates and commentary (multiple outlets) discuss valuation after a short-term rebound — useful for investors evaluating entry points but not an immediate catalyst. TD Cowen Model Update (InsiderMonkey)
• Neutral Sentiment: Reported February short-interest data is anomalous/zero in the feed (no meaningful short-interest signal to drive moves). (Internal data)
• Negative Sentiment: Press coverage highlights disclosure probes into Lantheus, raising questions about management credibility and the reliability of Pylarify forecasts — this is a reputational and regulatory risk that could pressure the stock if investigations produce adverse findings. Disclosure Probes Coverage

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on LNTH. Truist Financial increased their price objective on shares of Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Finally, Mizuho raised their target price on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $78.00.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.